Risk factors for glucocorticoid-induced diabetes mellitus in non-Hodgkin lymphoma after CHOP-like chemotherapy: analysis of 102 cases

Abstract

Objective To investigate the clinical characteristics and related risk factors of glucocorticoid-induced diabetes mellitus (GIDM) in the patients with non-Hodgkin lymphoma (NHL) who were treated with CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone)-like chemotherapy. Methods Clinical data of 102 NHL patients undergoing CHOP-like chemotherapy in our department from January 2015 to March 2019 were collected in this study. After the patients with a known history of DM and impaired fasting glucose were excluded, diagnosis of DM was made according to the American Diabetes Association's criteria. The incidence and clinical characteristics of GIDM were observed. The risk factors of secondary GIDM were analyzed by univariate and multivariate analysis. Results Forty-four out of 102 patients (43.1%) developed GIDM, and the chemotherapy efficacy in the GIDM patients was worse than that of non-GIDM patients (P < 0.05). Univariate analysis indicated that age ≥60 years, female, glycated hemoglobin (HbA1c) level ≥6.1%, hypertension at admission or history of hypertension, hypertriglyceridemia, and fasting plasma glucose (FPG) level ≥5.0 mmol/L were high risk factors for GIDM (P < 0.05). Moreover, multivariate analysis revealed that age ≥60 years, FPG level ≥5.0 mmol/L, HbA1c level ≥6.1%, hypertriglyceridemia and history of hypertension were independent risk factors of GIDM. Conclusion NHL patients with older age, higher blood glucose, and accompanied with abnormal blood lipid and blood pressure are more likely to develop GIDM during CHOP-like chemotherapy.

Keywords

• glucocorticoid-induced diabetes mellitus
• non-hodgkin lymphoma
• chop-like chemotherapy
• risk factors